文献速递妇科

癌症患者中尼拉帕利相关高血压:基于FAERS数据库的药物警戒分析及随机对照试验的Meta分析

Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
PubMed 文献 · Gynecol Oncol · 2024-01-31

基于FAERS数据库的药物警戒分析和5项随机对照试验的Meta分析显示,尼拉帕利相关高血压报告比值比ROR为2.85(95%CI 2.69-3.01),显著高于其他PARP抑制剂;与安慰剂相比,尼拉帕利显著增加高血压风险(OR 2.84,95%CI 2.17-3.72,P<0.01),高血压发生率为16.9%(95%CI 14.9-18.9)。

要点

  • FAERS数据库中尼拉帕利相关高血压病例1196例,报告比值比ROR为2.85(95%CI 2.69-3.01),P<0.01。
  • 5项随机对照试验Meta分析显示,尼拉帕利较安慰剂显著增加高血压风险(OR 2.84,95%CI 2.17-3.72,P<0.01)。
  • 尼拉帕利所致高血压发生率为16.9%(95%CI 14.9-18.9;I²=34%)。

核心结论

  • 高血压是尼拉帕利相较于其他PARP抑制剂更具特征性的不良事件。
  • 尼拉帕利显著增加高血压风险,临床用药中需要早期识别和管理。

研究设计与样本

  • 基于FAERS数据库的观察性、回顾性药物警戒研究,提取2017年第一季度至2023年第一季度尼拉帕利相关高血压病例进行不一致性分析。
  • 另对PubMed、Embase和Web of Science自建库至2023年5月31日发表的尼拉帕利治疗癌症的随机对照试验进行Meta分析,主要结局为尼拉帕利相关高血压的发生率和风险。

主要发现

  • FAERS中发现1196例与尼拉帕利治疗相关的高血压病例。
  • 尼拉帕利的不一致性水平最高,报告比值比ROR为2.85(95%CI 2.69-3.01),提示其较其他PARP抑制剂更易引起高血压(P<0.01)。
  • 安全性Meta分析纳入5项报告高血压的关键随机对照试验,与安慰剂相比,尼拉帕利显著增加高血压风险(OR 2.84,95%CI 2.17-3.72,P<0.01),研究间未观察到异质性(I²=0%,χ²=2.02,P=0.73)。
  • 尼拉帕利所致高血压的发生率为16.9%(95%CI 14.9-18.9;I²=34%)。

临床怎么用

  • 原文结论认为尼拉帕利显著增加高血压风险,临床用药中需要早期识别和管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Niraparib plays a crucial role in the treatment of ovarian cancer. A comprehensive understanding of the incidence and risk of hypertension associated with niraparib would be of vital importance to healthcare practitioners. METHODS: In this study, an observational, retrospective, pharmacovigilance study was conducted based on the FDA Adverse Event Reporting System (FAERS) database. Cases of hypertension related to niraparib were extracted for disproportionality analysis from the first quarter (Q1) of 2017 to Q1 of 2023. Moreover, a separate meta-analysis was performed using the randomized controlled trials (RCTs) on niraparib for cancer treatment published in PubMed, Embase, and Web of Science from inception to May 31st, 2023. The primary outcomes were the incidence and risk of hypertension associated with niraparib. RESULTS: In the FAERS, 1196 hypertension cases were found to be related to niraparib treatment. Notably, niraparib exhibited the highest level of disproportionality, as indicated by a reporting odds ratio (ROR) of 2.85 (95% CI, 2.69-3.01), suggesting a greater likelihood of causing hypertension compared to other poly-ADP-ribose polymerase (PARP) inhibitors (P < 0.01). Our safety meta-analysis included five pivotal RCTs of niraparib that reported hypertension. In comparison to placebo treatment, the meta-analysis demonstrated a significant increase in the risk of hypertension with niraparib (OR 2.84 [95% CI, 2.17-3.72], P < 0.01), with no heterogeneity observed among the studies (I2 = 0%, χ2 = 2.02, P = 0.73). The incidence of niraparib-induced hypertension was determined to be 16.9% (95% CI, 14.9-18.9; I2 = 34%). CONCLUSIONS: These findings suggest that hypertension is a distinctive adverse event associated with niraparib compared to other PARP inhibitors. Niraparib significantly increases the risk of hypertension that needs early recognition and management in clinical medication.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chen W, Xie J, Gao C, et al. Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials. Gynecol Oncol. 2024. PMID: 38295607. doi:10.1016/j.ygyno.2024.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。